Novel peptidomimetics for inhibition of HER2:HER3 heterodimerization in HER2-positive breast cancer

Chemical Biology and Drug Design

Volumn 85, Issue 6, 2015, Pages 702-714

  Kanthala, Shanthi ^a   Banappagari, Sashikanth ^a   Gokhale, Ameya ^a   Liu, Yong Yu ^a   Xin, Gu ^b   Zhao, Yunfeng ^b   Jois, Seetharama ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

breast cancer; HER2; HER3; peptidomimetic; protein protein interaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PEPTIDOMIMETIC AGENT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN-FRAGMENT COMPLEMENTATION ASSAY; SERUM; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR MODEL; NUDE MOUSE; PATHOLOGY; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; PEPTIDOMIMETICS; PROTEIN INTERACTION MAPS; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84929379646     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12453     Document Type: Article

References (50)

1. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J., (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res; 61: 4744-4749.
2. Slamon D.J., (1987) Proto-oncogenes and human cancers. N Engl J Med; 317: 955-957.
3. Tebbutt N., Pedersen M.W., Johns T.G., (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer; 13: 663-673.
4. Chang J.C., (2007) HER2 inhibition: from discovery to clinical practice. Clin Cancer Res; 13: 1-3.
5. Niehans G.A., Singleton T.P., Dykoski D., Kiang D.T., (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst; 85: 1230-1235.
6. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S., (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell; 12: 541-552.
7. Baselga J., Swain S.M., (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer; 9: 463-475.
8. Lu C., Mi L.Z., Grey M.J., Zhu J., Graef E., Yokoyama S., Springer T.A., (2010) Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol; 30: 5432-5443.
9. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S., (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell; 110: 775-787.
10. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L., (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol; 9: 16-32.
11. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W., (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res; 17: 5530-5537.
12. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M., (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res; 68: 5878-5887.
13. Shah D.R., Shah R.R., Morganroth J., (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf; 36: 413-426.
14. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X., (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell; 5: 317-328.
15. Harari D., Yarden Y., (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene; 19: 6102-6114.
16. Nahta R., Esteva F.J., (2006) Herceptin: mechanisms of action and resistance. Cancer Lett; 232: 123-138.
17. Esserman L.J., DeMichele A., (2014) Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res; 20: 3632-3636.
18. Sathish J.G., Sethu S., Bielsky M.C., de Haan L., French N.S., Govindappa K., Green J., et al,. (2013) Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov; 12: 306-324.
19. Hruby V.J., (2002) Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov; 1: 847-858.
20. Hruby V.J., Cai M., Nyberg J., Muthu D., (2011) Approaches to the rational design of selective melanocortin receptor antagonists. Expert Opin Drug Discov; 6: 543-557.
21. Marschutz M.K., Zauner W., Mattner F., Otava A., Buschle M., Bernkop-Schnurch A., (2002) Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides; 23: 1727-1733.
22. Banappagari S., Ronald S., Satyanarayanajois S.D., (2010) A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein. J Biomol Struct Dyn; 28: 289-308.
23. Banappagari S., Ronald S., Satyanarayanajois S.D., (2011) Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. MedChemComm; 2: 752-759.
24. Banappagari S., Corti M., Pincus S., Satyanarayanajois S., (2012) Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J Biomol Struct Dyn; 30: 594-606.
25. Kanthala S., Gauthier T., Satyanarayanajois S., (2013) Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. Biopolymers; 101: 693-702.
26. Banappagari S., McCall A., Fontenot K., Vicente M.G., Gujar A., Satyanarayanajois S., (2013) Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain. Eur J Med Chem; 65C: 60-69.
27. Tolliday N., (2010) High-throughput assessment of mammalian cell viability by determination of adenosine triphosphate levels. Curr Protoc Chem Biol; 2: 153-161.
28. Majumdar S., Anderson M.E., Xu C.R., Yakovleva T.V., Gu L.C., Malefyt T.R., Siahaan T.J., (2012) Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis. J Pharm Sci; 101: 3275-3291.
29. Bhinge K.N., Gupta V., Hosain S.B., Satyanarayanajois S.D., Meyer S.A., Blaylock B., Zhang Q.J., Liu Y.Y., (2012) The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase. Int J Biochem Cell Biol; 44: 1770-1778.
30. Patwardhan G.A., Zhang Q.J., Yin D., Gupta V., Bao J., Senkal C.E., Ogretmen B., Cabot M.C., Shah G.V., Sylvester P.W., Jazwinski S.M., Liu Y.Y., (2009) A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS ONE; 4: e6938.
31. Hao Y., Wang C., Cao B., Hirsch B.M., Song J., Markowitz S.D., Ewing R.M., Sedwick D., Liu L., Zheng W., Wang Z., (2013) Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer Cell; 23: 583-593.
32. Foy K.C., Wygle R.M., Miller M.J., Overholser J.P., Bekaii-Saab T., Kaumaya P.T., (2013) Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol; 191: 217-227.
33. Wainberg Z.A., Anghel A., Desai A.J., Ayala R., Luo T., Safran B., Fejzo M.S., Hecht J.R., Slamon D.J., Finn R.S., (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res; 16: 1509-1519.
34. Formisano L., Nappi L., Rosa R., Marciano R., D'Amato C., D'Amato V., Damiano V., Raimondo L., Iommelli F., Scorziello A., Troncone G., Veneziani B., Parsons S.J., De Placido S., Bianco R., (2014) Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res; 16: R45.
35. Wallace J., (2000) Humane endpoints and cancer research. ILAR J; 41: 87-93.
36. Yin H., Chu A., Li W., Wang B., Shelton F., Otero F., Nguyen D.G., Caldwell J.S., Chen Y.A., (2009) Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem; 284: 12328-12338.
37. Fredriksson S., Gullberg M., Jarvius J., Olsson C., Pietras K., Gustafsdottir S.M., Ostman A., Landegren U., (2002) Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol; 20: 473-477.
38. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., Dennis P.A., Lipkowitz S., (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res; 61: 4892-4900.
39. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr, Leahy D.J., (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature; 421: 756-760.
40. Hess S., Ovadia O., Shalev D.E., Senderovich H., Qadri B., Yehezkel T., Salitra Y., Sheynis T., Jelinek R., Gilon C., Hoffman A., (2007) Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem; 50: 6201-6211.
41. Hunter H.N., Jing W., Schibli D.J., Trinh T., Park I.Y., Kim S.C., Vogel H.J., (2005) The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta; 1668: 175-189.
42. Tugyi R., Uray K., Ivan D., Fellinger E., Perkins A., Hudecz F., (2005) Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci USA; 102: 413-418.
43. Landgraf R., (2007) HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res; 9: 202.
44. Roskoski R. Jr, (2013) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res; 79C: 34-74.
45. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R., (2002) Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem; 277: 28330-28339.
46. Saxon M.L., Lee D.C., (1999) Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. J Biol Chem; 274: 28356-28362.
47. Kumagai T., Katsumata M., Hasegawa A., Furuuchi K., Funakoshi T., Kawase I., Greene M.I., (2003) Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proc Natl Acad Sci USA; 100: 9220-9225.
48. Ferguson K.M., (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys; 37: 353-373.
49. Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J., (2007) Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell; 130: 323-334.
50. Dawson J.P., Berger M.B., Lin C.C., Schlessinger J., Lemmon M.A., Ferguson K.M., (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol; 25: 7734-7742.